Incivek Black Box Creates Fallout Risk For Vertex, FDA On Rash-related Fatalities
This article was originally published in The Pink Sheet Daily
Executive Summary
For Vertex, the key question is how much is physician and patient concern about the adverse events is already reflected in the softening sales of the hepatitis C drug; for FDA, the question is how effective will label-based risk management be.